Ulocuplumab

Ulocuplumab (INN;[1] development code MDX-1338) is a monoclonal antibody designed for the treatment of hematologic malignancies.[2]

Ulocuplumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetC-X-C chemokine receptor type 4
Clinical data
Other namesMDX-1338
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6486H9960N1720O2046S46
Molar mass146243.78 g·mol−1

This drug was developed by Bristol-Myers Squibb.

References
  1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Ulocuplumab, American Medical Association.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.